This week, the ratings of 10 biotechnology stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, CEL-SCI Corporation (CVM) falls to a D (“sell”), worse than last week’s grade of C (“hold”). CEL-SCI is developing new immune system based treatments for cancer and infectious diseases. In Portfolio Grader’s specific subcategories of Equity and Cash Flow, CVM also gets F’s. For more information, get Portfolio Grader’s complete analysis of CVM stock.

EPIRUS Biopharmaceuticals, Inc. (EPRS) earns a D this week, falling from last week’s grade of C. The stock also gets an F in Earnings Revisions. Shares of the stock have been changing hands at an unusually rapid pace, three times the rate of the week prior. To get an in-depth look at EPRS, get Portfolio Grader’s complete analysis of EPRS stock.

This is a rough week for Ohr Pharmaceutical Inc (OHRP). The company’s rating falls to D from the previous week’s C. Ohr Pharmaceutical develops pharmaceuticals for wound care and to treat cachexia. The stock gets F’s in Earnings Revisions and Equity. For more information, get Portfolio Grader’s complete analysis of OHRP stock.

Trius Therapeutics, Inc. (TSRX) earns a D this week, moving down from last week’s grade of C. Trius Therapeutics is a biopharmaceutical company. The stock gets F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. To get an in-depth look at TSRX, get Portfolio Grader’s complete analysis of TSRX stock.

The rating of Vical Incorporated (VICL) declines this week from a C to a D. Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The stock gets F’s in Equity and Cash Flow. Shares of the stock are changing hands at twice the rate they were a week ago. For more information, get Portfolio Grader’s complete analysis of VICL stock.

Tenax Therapeutics, Inc. (TENX) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). The stock receives F’s in Earnings Momentum, Earnings Revisions and Equity. Cash Flow and Sales Growth also get F’s. To get an in-depth look at TENX, get Portfolio Grader’s complete analysis of TENX stock.

This week, Synergy Pharmaceuticals, Inc. (SGYP) drops from a D to an F rating. Synergy Pharmaceuticals is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. The stock gets F’s in Equity and Cash Flow. As of March 25, 2015, 14.7% of outstanding Synergy Pharmaceuticals, Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of SGYP stock.

Verastem, Inc. (VSTM) is having a tough week. The company’s rating falls from a D to an F. Verastem is a biopharmaceutical company which is focused on discovering and developing novel drugs that selectively target cancer stem cells in breast and other cancers along with proprietary companion diagnostics. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at VSTM, get Portfolio Grader’s complete analysis of VSTM stock.

Celldex Therapeutics, Inc. (CLDX) gets weaker ratings this week as last week’s C drops to a D. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The stock also gets an F in Equity. As of March 25, 2015, 19.8% of outstanding Celldex Therapeutics, Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of CLDX stock.

This week, Trevena, Inc.’s (TRVN) rating worsens to a D from the company’s C rating a week ago. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at TRVN, get Portfolio Grader’s complete analysis of TRVN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.